Overview
Legal name
ABFERO LIMITED
Region
South East England
Registered address
Unknown
Insolvency history
No
Company
Active
LTD
Company profile
Abfero Limited
Abfero Pharmaceuticals | Iron as a Therapeutic Target
Our mission is to develop best-in-class, safe and effective oral iron chelators for the treatment of diseases of iron overload.
CRN
11255897
Founded
2018
Age
7
Company events
Reference milestones and recent Companies House filing stream events.
1 event
14 Mar
2018
Incorporated
InceptionCompany registered at Companies House
Public funding
1 award
First funded
2020
Funded years
2020
Age at first award
2 years
Projects
2020
EU-Funded
Lead participant
Novel Parkinson’s Disease therapy targeting iron-related cell death and alphasynuclein aggregation (PD-IRONSYN)
1 Nov 2020 to 31 Oct 2023
Awarded
£252,515
Total cost £420,858
Product types
EU-Funded